ResApp Health Ltd (ASX:RAP) is preparing to outline preliminary results from its adult clinical study.
ResApp has a unique strategy as a digital health company developing smartphone applications for the diagnosis and management of respiratory disease.
The ASX has granted the company a trading halt to prepare, with its shares placed in pre-open.
The halt will remain in place until the opening of trade on Wednesday 22nd June 2016, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.